Стратифікація ризику за генотипуванням ВПЛ — how extended HPV genotype detection reshapes triage decisions beyond a single pooled "high-risk positive" result
Cervical screening assays typically report a pooled result across 12–14 oncogenic HPV genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. A "positive" result tells a clinician a high-risk type is present — but treating all 14 types as interchangeable discards a large amount of risk information, because their contribution to cervical cancer varies by roughly an order of magnitude across the group.
Standard hrHPV assays were designed primarily to maximize sensitivity for detecting any oncogenic infection, using a pooled "Other HR-HPV" channel alongside separate 16 and 18 channels. That pooled channel treats a type with modest longitudinal cancer risk the same as a type with substantially higher risk, simply because both clear the "oncogenic" threshold used for assay design decades ago.
Large prospective cohort studies (e.g., the Kaiser Permanente Northern California cohort, and pooled European screening cohorts) that followed genotype-specific outcomes over 10+ years found the cumulative risk of CIN3+ varies severalfold across the "other high-risk" group — types like 31, 33, 45, 52, and 58 sit in a meaningfully higher-risk tier than types like 39, 51, 56, 59, 66, and 68.
This matters clinically because triage decisions built only on a pooled positive/negative call cannot distinguish a patient carrying a modest-risk type from one carrying a type with materially elevated risk — both simply read "positive."
Working from longitudinal absolute-risk data, high-risk genotypes are commonly grouped into informal tiers for triage discussions:
• Tier A (highest risk): HPV 16, HPV 18 — reported individually in essentially every modern platform • Tier B (elevated-but-lower-than-16/18): HPV 31, 33, 45, 52, 58 — sometimes called the "second-tier" oncogenic types • Tier C (lower relative risk within the high-risk group): HPV 35, 39, 51, 56, 59, 66, 68
These tiers are not fixed by regulatory standard — different platforms and guideline bodies partition them slightly differently — but the ordering is consistent across most published longitudinal data: 16 and 18 sit clearly above the rest.
HPV 16 and HPV 18 are, by a wide margin, the two most consequential high-risk genotypes. Together they are found in roughly two-thirds to three-quarters of cervical cancers globally, despite representing only two of the 12–14 genotypes captured by pooled high-risk testing. Detecting either one specifically identifies a patient whose immediate risk of underlying or future high-grade disease is materially higher than a patient positive for a different high-risk type.
The ATHENA trial and multiple subsequent validation cohorts established the foundational evidence for individually reporting HPV 16 and 18 in screening. Women who tested positive for HPV 16 had a substantially higher immediate risk of CIN3+ (cervical intraepithelial neoplasia grade 3 or worse) than women positive for any pooled "other high-risk" result — high enough that many guideline bodies concluded HPV 16 positivity alone justified direct colposcopy referral, without waiting for a cytology result.
HPV 18 carries a related but distinct significance: it is disproportionately associated with adenocarcinoma and adenocarcinoma-in-situ, lesions that arise higher in the endocervical canal and are more likely to be missed by cytology sampling (which primarily samples the ectocervix). This means HPV 18 positivity can carry meaningful risk even when cytology looks reassuring — a scenario where a genotype-blind pooled result would understate the concern.
Because 16 and 18 carry higher immediate risk than the other 12 high-risk types combined on a per-type basis, most contemporary risk-based management guidelines (e.g., ASCCP risk-based consensus guidelines) treat an HPV 16 or 18 positive result as sufficient, on its own, to recommend colposcopy — independent of the cytology result. A positive result for one of the other high-risk types, by contrast, is generally not treated as automatically colposcopy-triggering; it instead prompts a secondary triage step such as reflex cytology or a shortened repeat-testing interval.
This is the central practical consequence of genotyping: it converts a single binary "high-risk positive" signal into a risk-stratified signal that materially changes what happens next for the patient.
A positive pooled high-risk HPV result with normal cytology and a positive HPV 16 result with normal cytology are not clinically equivalent — the latter carries enough independent risk that genotyping alone can be the deciding factor for immediate colposcopy referral in many current guidelines.
Genotyping does not just add information to a chart — it changes which triage branch a patient enters. A positive HPV 16/18 result can send a patient straight to colposcopy, while a positive result for another high-risk type routes through an intermediate triage step (typically reflex cytology or a repeat co-test) before a colposcopy decision is made. This branching is the operational core of genotype-informed screening.
A genotype-informed triage algorithm typically forks immediately after the HPV result returns:
Branch 1 — HPV 16 or HPV 18 positive: • Routed directly to colposcopy referral, regardless of cytology result • Rationale: the absolute risk of underlying CIN3+ in this group is high enough that an intermediate triage step would delay detection of clinically significant disease without meaningfully reducing unnecessary colposcopies
Branch 2 — positive for a high-risk type other than 16/18: • Routed to reflex cytology (if not already performed as co-testing) or a defined repeat-testing interval • If cytology is abnormal (ASC-US or worse): escalate to colposcopy • If cytology is normal: repeat HPV/cytology co-testing at a shortened interval (commonly ~1 year) rather than immediate colposcopy
This branching reduces the total number of colposcopy referrals compared with a strategy that sends every HPV-positive patient to colposcopy, while still capturing the highest-risk patients (16/18-positive) immediately.
Colposcopy is not a benign step — it carries patient anxiety, cost, and a nontrivial burden on colposcopy clinic capacity, especially in high-volume screening programs. Sending every high-risk-HPV-positive patient straight to colposcopy would substantially over-refer patients who are unlikely to have high-grade disease, since the "other high-risk" group as a whole carries lower absolute risk than 16/18.
At the same time, delaying colposcopy for HPV 16/18-positive patients behind a reflex cytology step risks missing early high-grade lesions in a genotype group known to progress with disproportionate frequency and speed. The genotype-specific branch point is therefore a deliberate trade-off: use the highest-resolution risk signal available (genotype) to decide who bypasses intermediate triage, and use a lower-cost secondary signal (cytology) to further stratify the remaining, comparatively lower-risk group.
Some molecular platforms report more than the standard three-channel result (16 / 18 / pooled-other). Extended genotyping panels individually identify additional types — commonly grouping 31, 33, 45, 52, and 58 as a distinct "elevated second tier" — offering finer risk stratification than a single pooled channel. Whether this additional granularity should change management, and for which patient populations, remains an active area of clinical research.
Extended genotyping platforms vary in how finely they subdivide the high-risk group:
• Partial extended panels: report HPV 16, HPV 18, plus a secondary pooled group covering the "second tier" types (31, 33, 45, 52, 58) separately from the remaining lower-tier types • Fully extended panels: report each of the 12–14 high-risk types individually, generating a complete genotype profile per patient • Some platforms additionally report select probable/possible high-risk types (e.g., 26, 53, 67, 70, 73, 82) that are not universally classified as high-risk but appear in some regional guideline lists
The practical benefit of extended genotyping is the ability to identify patients whose "other high-risk" result actually belongs to the elevated second tier — information a standard three-channel assay cannot provide, since it collapses that patient into the same pooled category as a patient carrying a comparatively lower-risk type.
The clinical case for HPV 16/18 individual reporting is well established by large, mature longitudinal cohorts and is broadly reflected in current risk-based management guidelines. The case for acting on second-tier genotype information (31/33/45/52/58 vs. the remaining lower-tier types) is comparatively newer and less uniformly incorporated into guideline algorithms.
Open questions include: whether second-tier-positive, cytology-normal patients should be triaged differently than other-high-risk-positive, cytology-normal patients; how much additional colposcopy referral reduction (or lesion detection gain) extended genotyping actually delivers in prospective practice; and how extended panels should be validated across diverse populations, since genotype prevalence and risk vary somewhat by region.
In practice, extended genotyping is increasingly available on modern platforms, and many laboratories now report it — but treating its output as automatically actionable beyond the well-established 16/18 distinction requires care until guideline bodies formally incorporate the additional tiers.
Extended genotyping increases the resolution of the risk signal, but resolution is only clinically useful once it is tied to a validated management action. For 16/18, that link is well established; for the second tier, it is still maturing.
No single result decides management in isolation. A genotype-informed algorithm combines the HPV genotype result, the cytology result, and relevant patient history (prior screening results, vaccination status, immune status) to produce a single risk-based recommendation: direct colposcopy referral, a shortened repeat-testing interval, or reassurance with a routine screening interval. This combined approach is the practical endpoint of everything genotyping makes possible.
Contemporary risk-based cervical screening guidelines (most explicitly the ASCCP risk-based management consensus guidelines) are built on a simple organizing principle: management decisions should be driven by a patient's estimated absolute risk of CIN3+, not by which specific combination of tests produced that risk estimate. Two patients with the same estimated risk should receive the same recommendation, even if one arrived at that risk via HPV 16 positivity with normal cytology and the other arrived at it via an other-high-risk-type result combined with abnormal cytology.
This is why genotype and cytology are combined rather than evaluated independently: genotype contributes an intrinsic, type-specific risk weight, while cytology contributes an independent morphological signal. When both point toward elevated risk, the combined estimate crosses the colposcopy threshold faster than either input would alone.
Genotype and cytology are the two dominant inputs, but a full risk-based algorithm also incorporates:
• Screening history: a current result following a documented history of normal results carries lower risk than the same result as a first-time or previously-abnormal-history finding • HPV vaccination status: vaccination against 16/18 (and, for nonavalent vaccines, additional high-risk types) shifts population-level type distribution and can be factored into some risk models, though genotyping still resolves individual infections regardless of vaccination status • Immune status: immunocompromised patients (e.g., HIV-positive, transplant recipients) carry independently elevated risk and are typically managed with shorter intervals regardless of genotype/cytology combination • Age: risk-benefit tradeoffs around colposcopy referral shift with age, particularly around the boundary between routine screening ages and extended-interval-eligible groups
The output of the combined algorithm is therefore not a lookup of genotype alone, but a synthesis: genotype sets the baseline risk weight, cytology and history adjust it, and the final estimate is mapped to one of the three standard pathways.
Direct colposcopy referral: reserved for combinations estimated to carry immediate CIN3+ risk above the colposcopy action threshold — most reliably triggered by HPV 16/18 positivity (with or without abnormal cytology), or by an other-high-risk-type result combined with abnormal cytology.
Repeat testing at a shortened interval (commonly ~1 year): reserved for combinations carrying intermediate risk — most commonly an other-high-risk-type positive result with normal cytology — where immediate colposcopy is not clearly justified but routine-interval reassurance would be premature.
Routine screening interval / reassurance: reserved for HPV-negative results, where the well-established long-term negative predictive value of HPV testing supports extending the interval to several years regardless of genotype panel used, since no oncogenic type was detected.
The genotype-informed management algorithm is not a replacement for clinical judgment — it is a structured way of translating a growing amount of molecular information (genotype tiers, extended panels) into a small number of clear, actionable recommendations that a clinician and patient can act on.